Breast cancer

Management of HER2+ MBC

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Educational Objective: Gain insight into the appropriateness of systemic therapies for patients with HER2+ metastatic breast cancer (MBC), mainly focussing on patients without brain metastases.
Specialty: Medical oncology, Clinical oncology
Target Audience: CME (basic, intermediate), Residents (senior)
Latest update: November 2023
Background:

In a short window of time, new drugs for HER2+ MBC have become available. This created both clinical opportunity and uncertainty regarding the selection and sequencing of therapy.

Regulatory approval status of targeted therapies for HER2+ MBC (indications limited to HER2+ MBC setting, status 3 October 2023)